125 related articles for article (PubMed ID: 20417353)
1. Current problems with systemic treatment of advanced hepatocellular cancer.
He AR; Soe K; El Zouhairi M
Curr Probl Cancer; 2010; 34(2):131-49. PubMed ID: 20417353
[No Abstract] [Full Text] [Related]
2. [Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Yu L; Dai Z; Zhou J; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):475-7. PubMed ID: 19567036
[No Abstract] [Full Text] [Related]
3. FDA approves sorafenib for patients with inoperable liver cancer.
Lang L
Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
[No Abstract] [Full Text] [Related]
4. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Kuzuya T; Tsuchiya K; Izumi N
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
[No Abstract] [Full Text] [Related]
6. Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword.
Kummar S
Curr Probl Cancer; 2010; 34(2):130. PubMed ID: 20417352
[No Abstract] [Full Text] [Related]
7. [Hepatocellular carcinoma management in the era of sorafenib].
Rosmorduc O
Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
[No Abstract] [Full Text] [Related]
8. Signaling pathways in hepatocellular carcinoma.
Sia D; Villanueva A
Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Kelley RK; Venook AP
J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
[No Abstract] [Full Text] [Related]
12. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
13. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Chiou JF; Tai CJ; Huang MT; Wei PL; Wang YH; An J; Wu CH; Liu TZ; Chang YJ
Ann Surg Oncol; 2010 Feb; 17(2):603-12. PubMed ID: 19830497
[TBL] [Abstract][Full Text] [Related]
14. New drugs for the treatment of hepatocellular carcinoma.
Boucher E; Forner A; Reig M; Bruix J
Liver Int; 2009 Jan; 29 Suppl 1():148-58. PubMed ID: 19207980
[TBL] [Abstract][Full Text] [Related]
15. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Lapecorella M; Napolitano M; Tudini M; Bruera G; Lucchesi A; Giordano AV; Mariani G; Ricevuto E
Haemophilia; 2010 Jan; 16(1):185-7. PubMed ID: 19804385
[No Abstract] [Full Text] [Related]
17. From a cancer drug fund to value based pricing of drugs.
Duerden M
BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
[No Abstract] [Full Text] [Related]
18. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
[No Abstract] [Full Text] [Related]
19. Drug therapy: sorafenib.
Finn RS
Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
[No Abstract] [Full Text] [Related]
20. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
